Codexis Announces Completion of CodeEvolver® License Technology Transfer with Global Pharmaceutical Leader
July 14 2021 - 4:05PM
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company
enabling the promise of synthetic biology, announced the completion
of the CodeEvolver® platform technology transfer with Novartis
Pharma AG (“Novartis”) today. In May 2019, the two companies signed
a platform technology transfer and license agreement, under which
Novartis has a non-exclusive license to CodeEvolver® to develop
novel performance enzymes for use in the manufacture of
pharmaceutical products.
“We are pleased to have completed the
CodeEvolver® installation for Novartis, enabling our long-time
customer to leverage Codexis’ proprietary enzyme engineering
technology,” said Stefan Lutz, Senior Vice President of Research of
Codexis. “Compared to using traditional, non-enzymatic chemistry,
CodeEvolver®-improved enzymes and processes can reduce capital
requirements, and enable higher yielding processes, with reduced
energy usage and lower waste generation. This is our third
licensing collaboration for a customer to bring CodeEvolver®
technology in-house, but the first one we have had to implement
virtually; I’m extremely proud of how our teams collaborated to
ensure a successful and efficient technology transfer, despite the
challenges of the pandemic.”
About Codexis
Codexis is a leading enzyme engineering company
leveraging its proprietary CodeEvolver® platform to discover and
develop novel, high performance enzymes and novel biotherapeutics.
Codexis enzymes have applications in the sustainable manufacturing
of pharmaceuticals, food, and industrial products; the creation of
the next generation of life science tools; and as biologic
therapeutics and in gene therapy. The Company’s unique enzymes
drive improvements such as reduced energy usage, waste generation
and capital utilization, higher yields, higher fidelity
diagnostics, and more efficacious therapeutics. Codexis enzymes
enable the promise of synthetic biology to improve the health of
people and the planet. For more information, visit
www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Codexis, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. You should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond Codexis’ control and that could materially affect actual
results. Factors that could materially affect actual results
include, among others: Codexis’ dependence on its licensees and
collaborators; Codexis’ dependence on a limited number of products
and customers and potential adverse effects to Codexis’ business if
its customers’ products are not received well in the markets.
Additional information about factors that could materially affect
actual results can be found in Codexis’ Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on March
1, 2021, and in Codexis’ Quarterly Report on Form 10-Q filed with
the SEC on May 7, 2021, including under the caption “Risk Factors,”
and in Codexis’ other periodic reports filed with the SEC. Codexis
expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Relations Contact:Argot
PartnersStephanie Marks/Carrie
McKimCodexis@argotpartners.com (212) 600-1902
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Apr 2023 to Apr 2024